I am a healthcare professional

Notice


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.


Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.


By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


Cookies


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.


You can find out more about cookies by browsing our Privacy Policy.

 

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Roche and Genentech at

FLORetina 2025

-
Coming soon
09:00 AM
Duration 6hrs Florence, Italy
Assessing a 36-Week Refill-Exchange Regimen for the PDS in Patients With Up to 2 Years’ Diagnosis of Neovascular Age-Related Macular Degeneration: Phase 3b Sightspire Trial
Caporossi T, Holz FG, Khanani AM, Lai TYY, Paudel N, Somkijrungroj T, Yoon YH, Zinkernagel MS, Dakouras A, Foxton RH, Liu B, Tian K

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
07:12 AM
Duration 3mins Fortezza da Basso
12-Month Real-World Clinical and Anatomical Outcomes With Faricimab▼ in Patients With nAMD or DME From a Global, Prospective Observational Study: The VOYAGER Study
Mariacristina Parravano, Bailey C, Chaikitmongkol V, Chaudhary V, Chi G, Downey A, Finger R, Ishida S, Kardatzke D, Koh A, Lövestam-Adrian M, Luna Pinto J, Schmitz-Valckenberg S, Schweitzer J, Sheth V, Souied E, Guymer R

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
07:24 AM
Duration 3mins Fortezza da Basso
Machine Learning–Based 3D Volumetric Analysis of Pigment Epithelial Detachment Reduction With Faricimab▼ vs Aflibercept in TENAYA/LUCERNE
Elisabeth Pilotto, Paolo Lanzetta, Yoshihiro Yonekawa, Thomas Albrecht, Derrek Hibar, Huanxiang Lu, Shriji Patel, Ming Yang, Philippe Margaron

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
07:25 AM
Duration 5mins Fortezza da Basso
Quantitative Ultra-Widefield Fluorescein Angiography for the Assessment of Novel Biomarkers of Vascular Stability With Faricimab▼: A YOSEMITE/RHINE Post Hoc Analysis
Aleksandra Rachitskaya, Karen Matar, Asmita Indurkar, Lyndsey Della Vecchia, Reem Amine, John Mamone, Amy Tang, Kara Gibson, Nicholas Dagincourt, Florie A. Mar, Manuel Amador, Alexandra Warter, Dawn A. Sim, Justis P. Ehlers

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
07:39 AM
Duration 3mins Fortezza da Basso
Baseline and Early Treatment Response Variables Associated With Faricimab▼ Durability in Treatment-Naïve nAMD: TENAYA/LUCERNE Post Hoc Analyses
Riccardo Sacconi, Deepak Sambhara, Benjamin Bakall, Adrian Koh Hock Chuan, Eric Souied, Colin S. Tan, Priya Vakharia, Ming Yang, Shriji Patel, Philippe Margaron

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
08:06 AM
Duration 3mins Fortezza da Basso
Efficacy and Safety of Vamikibart in Patients With Uveitic Macular Edema: Week 16 Results From the Phase 3 MEERKAT and SANDCAT Trials
Elisabetta Miserocchi, Rahul Khurana, Carlos Pavesio, Nisha Acharya, Koh-hei Sonoda & Eric Suhler (first and last author on manuscript). Steeples L, Brittain C , Fauser S, Galloway D, Haskova Z, Harrell E, Mesquida M, Silverman D

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
08:09 AM
Duration 3mins Fortezza da Basso
Patient Preference for the PDS vs Intravitreal Injections: Year 2 Results From the Phase 3 Pagoda Trial in Patients With DME
Koh A, Chang M, Dennis M, Koh A, Baldonado K, Daly A, Jones M, Wallenstein G, Tian K, Lin A, Prager A

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
03:13 PM
Duration 3mins Fortezza da Basso
Robust Vision Gain and Anatomic Improvement With Faricimab▼ in Patients With PCV: Week 48 Results From SALWEEN
Adrian Koh, Gemmy Cheung, Shih-Jen Chen, Tomohiro Iida, Junyeop Lee, Won Ki Lee, Xiaorong Li, Paisan Ruamviboonsuk, Xiaodong Sun, Yasuo Yanagi, Ruobing Bai, Anh Nguyen Duc, Philippe Margaron, Timothy Y. Y. Lai

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
03:36 PM
Duration 3mins Fortezza da Basso
Impact of Improvements to Surgical Procedure on the Incidence of Endophthalmitis and Associated Outcomes of Patients in the PDS Clinical Development Programme
Dolz-Marco R, Chang M, Chaudhry N, Cheung CMG, Campochiaro P, Pieramici D, Regillo CD, Gune S, Jaycock P, Kardatzke DR, Prager AJ, Singh N

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
04:06 PM
Duration 3mins Fortezza da Basso
Reduced Hard Exudates and Microaneurysms With Faricimab▼ Compared With Aflibercept in YOSEMITE/RHINE Using Automated Segmentation of DME Lesions on Colour Fundus Photography
Christiana Dinah, Prethy Rao, Andreas Pollreisz, Dawn Sim, Ming Yang, Acner Camino Benech, Kara Gibson, Fethallah Benmansour

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
04:09 PM
Duration 3mins Fortezza da Basso
RHONE-X Extension Study: Clinical Improvements in Eyes With DME Switched From Aflibercept to Faricimab▼
Ermete Giancipoli, Goldberg R, Pearce I, Sheth V, Khanani AM, Jones C, Gibson K, Lai TTY, Schlottmann P, Starr MR, Sim DA

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
04:15 PM
Duration 3mins Fortezza da Basso
Comparative Efficacy of Faricimab▼ for the Treatment of Diabetic Macular Edema at 1 and 2 Years: A Systematic Literature Review and Network Meta-Analysis
Alessandro Arrigo, Barakat M, Siedlecki J, Buehrer C, Cox O, Gibson K, Holekamp N, Patel S, Mar F

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
09:18 AM
Duration 3mins Fortezza da Basso
Long-Term Efficacy and Safety of the Port Delivery Platform With Ranibizumab in Patients With nAMD: Results From the Ladder- and Archway-to-Portal Trials
Yuen Yew Sen, Khanani A, Graff J, Mittra R, Awh C, Regillo C, Kitchens J, Blotner S, Gune S, Heinrich D, LePogarm S, Yaqub M, Rabena M, Singh N

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar